Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.59 |
| ▸ | CCKBR | P32239 | 4/20 | 0.53 |
| ▸ | BRD4 | O60885 | 9/20 | 0.52 |
| ▸ | BRD2 | P25440 | 9/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 9/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | OXTR | P30559 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005691 | 0.91 | SENP1 (0.63) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL2525194 | 0.86 | SENP1 (0.55) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL6003842 | 0.86 | BRD4 (0.68) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL6005238 | 0.83 | SENP1 (0.56) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL15628273 | 0.79 | SENP1 (0.62) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL6006456 | 0.79 | SENP1 (0.52) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL15622216 | 0.78 | SENP1 (0.66) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL16979057 | 0.78 | SENP1 (0.66) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL6993452 | 0.77 | SCN9A (0.78) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL3788080 | 0.77 | SCN9A (0.78) | SENP1CCKBRBRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | SENP1 528/4885CCKBR 642/4885BRD4 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.